1 / 8

Gastroparesis Drugs Market Is Anticipated To Drive the Market Growth

Global Gastroparesis Market was valued at $4,667 million in 2016, and is projected to reach $6,486 million at a CAGR of 4.7% from 2017 to 2023.

newmarketindustry
Télécharger la présentation

Gastroparesis Drugs Market Is Anticipated To Drive the Market Growth

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Skim Met Gastroparesis Drugs Market Global Opportunity Analysis & Industry Forecast, 2014-2022 Opportunity Analysis and Industry Forecast, 2014 - 2022 Global Opportunity Analysis and Industry Forecast, 2014-2022 Opportunity Analysis and Industry Forecast, 2014-2022 Global Opportunity Analysis and Industry Forecast 2030 Global Opportunity Analysis and Industry Forecast, 2014-2022 Global Opportunity Analysis and Industry Forecast, 2014 - 2022 Global Opportunity Analysis and Industry Forecast, 2017-2023 Global Opportunity Analysis and Industry Forecast 2023 Pages:231 Tables:116 Charts:36

  2. Gastroparesis Drugs Market “Focus of manufacturers on development of novel drugs; such as camicinal, 5-HT4 receptor agonists, and ghrelin agonist; to treat gastroparesis would have a significant impact on the market growth throughout the forecast period.” Pallavi Jaiswal Senior Research Analyst, Healthcare Research at AMR

  3. Gastroparesis Drugs Market Gastroparesis Drugs Market was valued at $4,667 million in 2016, and is projected to reach $6,486 million at a CAGR of 4.7% from 2017 to 2023. Gastroparesis affects the normal spontaneous movement of the muscles of stomach and interferes with the normal digestion, thus causing nausea, vomiting, and problems related with blood sugar levels & nutrition. Gastroparesis is caused due to diabetes or can develop after surgery. Recently, advanced drugs such as metoclopramide, erythromycin, antiemetics, and others are developed to treat gastroparesis.

  4. Gastroparesis Drugs Market The major factors that drive the growth of the global gastroparesis drugs market are rise in number of surgeries that may lead to postoperative gastroparesis, increase in diabetic population, introduction of novel drugs, and surge in geriatric population. However, side effects associated with gastroparesis drugs and time-consuming regulatory approvals are expected to restrain the market growth. Conversely, huge untapped market potential in the emerging countries, such as China and India, and development of novel gastroparesis drugs are expected to provide lucrative opportunities to the market players. Download Request Sample: https://www.alliedmarketresearch.com/request-sample/4153

  5. Gastroparesis Drugs Market The prokinetic agents segment occupied the largest share in 2016, owing to the high usage, applicability, and availability of prokinetic agents for treating gastroparesis. Furthermore, the botulinum toxin injection segment is expected to grow at the highest CAGR of 5.6% from 2017 to 2023, and is anticipated to continue its dominance during the forecast period. The utilization rate of gastroparesis drugs for idiopathic gastroparesis is high, however post-surgical gastroparesis segment is expected to grow at a CAGR of 5.2% during the forecast period. This is attributed to increase in incidence of various types of surgeries, such as transplantation, which result in postsurgical gastroparesis. Download Request Sample: https://www.alliedmarketresearch.com/request-sample/4153

  6. Gastroparesis Drugs Market • Major Companies: • Allergan Plc. • Abbott Laboratories (Abbott Arzneimittel GmbH) • AstraZeneca Plc. • Cadila Pharmaceuticals Ltd. • ETX Pharma Inc • Evoke Pharma • GlaxoSmithKline Plc. • NeurogastrxInc. • Valeant Pharmaceuticals International Inc. • TheravanceBiopharma.

  7. Gastroparesis Drugs Market • Key findings of the Gastroparesis Drugs Market: • Prokinetic agents segment accounted for more than four-fifths share of the global gastroparesis drugs market in 2016. • Botulinum toxin injection segment is expected to grow at a CAGR of 5.6% from 2017 to 2023. • Idiopathic gastroparesis segment accounted for around 34.9% share of the global gastroparesis drugs market in 2016. • Hospitals accounted for nearly two-fifths share of the global gastroparesis drugs market in 2016. • Pharmacies segment is expected to grow at a CAGR of 5.0% from 2017 to 2023 • Send Enquiry on Report: https://www.alliedmarketresearch.com/purchase-enquiry/4153

  8. Gastroparesis Drugs Market • Contact: • David Correa • 5933 NE Win Sivers Drive • #205, Portland, OR 97220 • United States • Toll Free (USA/Canada): • +1-800-792-5285, +1-503-894-6022, +1-503-446-1141 • UK: +44-845-528-1300 • Hong Kong: +852-301-84916 • India (Pune): +91-20-66346060 • Fax: +1⟨855⟩550-5975 • help@alliedmarketresearch.com • Web: https://www.alliedmarketresearch.com

More Related